AML is a hematologic cancer that is clinically heterogeneous, with a wide range of clinical outcomes. DNA methylation changes are a hallmark of AML but are not routinely used as a criterion for risk ...
Bionano Symposium 2026 continues with Day 2: New Frontiers in Oncology and Bioprocessing Applications on February 24, 2026, from 7:00-10:00 AM PT. Attendees may also explore scientific posters ...
Bionano Genomics, Inc. (Nasdaq: BNGO) today announced highlights from the fourth and final day of Symposium 2026. Day 4 featured updates from some of the most advanced and high-volume cytogenetics and ...
Improved Outcome for Patients With Middle Ear Rhabdomyosarcoma: A Children’s Oncology Group Study PURPOSE: To determine the relationship between multiple genetic features, tumor morphology, and ...
Neuberg Sehgal Path Lab, a leading name in diagnostic services, has announces the launch of cutting-edge cytogenetics testing technology at its facilities in Mumbai. This advanced diagnostic tool is ...
Panelists discuss how NCCN guidelines are expected to incorporate quadruplet-based regimens as reasonable treatment approaches for transplant-ineligible patients, while emphasizing the need for ...
DUBLIN--(BUSINESS WIRE)--The "Cytogenetics - Technologies, Markets and Companies" report from Jain PharmaBiotech has been added to Research and Markets' offering. This report deals with cytogenetics ...
AZoLifeSciences on MSN
New gene-editing strategy to eliminate aggressive cancer cells
The initiation and severity of cancer are associated with the atypical behavior of specific genes, referred to as oncogenes. The most recognized of these changes is mutation; however, it is not the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results